In relation to whether it could be administered to age groups not so far the subject of an application by Pfizer, I'd just draw the member's attention to clause 4 of the bill. It does require the director-general, in issuing the notice, to have access to data to justify the notice that the director-general might give and having regard to the likely therapeutic value of the administration of the vaccine and any risk and that it's an appropriate measure. So the director-general has to be satisfied of that. In reality, that data is going to be most likely obtained from the pharmaceutical companies, so the director-general would be reliant on that. So unless there is some other source of data—